Longitude Capital Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
20
- Investments
-
133
- Portfolio
-
39
- Exits
-
84
Longitude Capital General Information
Description
Founded in 2006, Longitude Capital is a venture capital firm based in Menlo Park, California. The firm seeks to make investments in start-ups to growth companies in pharmaceuticals, biotechnology, healthcare devices, and life sciences sectors.
Contact Information
Website
www.longitudecapital.com
Year Founded
2006
Investor Status
Actively Seeking New Investments
Trade Association
New England Venture Capital Association (NEVCA)
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- 2740 Sand Hill Road
- 2nd Floor
- Menlo Park, CA 94025
- United States
+1 (650) 000-0000
Longitude Capital Investments (133)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| IntelyCare | 06-Apr-2022 | Later Stage VC | 00000 | Other Healthcare Technology Systems | Generating Revenue | |
| 0000000 | 05-Apr-2022 | 00000 00000 | 0000 | Therapeutic Devices | Generating Revenue | 0000000 000000 |
| 00 00000 000000 00 | 15-Mar-2022 | 00000 00000 | 00.000 | Practice Management (Healthcare) | Generating Revenue | |
| 0000000 | 23-Feb-2022 | 00000 00000 | 00000 | Clinics/Outpatient Services | Generating Revenue | 0000000 00000000 00 |
| 0000 | 15-Feb-2022 | 00000 00000 | 00000 | Therapeutic Devices | Generating Revenue | 000000 000000 |
| 00000000 000000000 | 22-Jan-2022 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 2 | 0000000 0000000 |
| 000000 000 | 05-Jan-2022 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 0000 0000000000 00 |
| 0000000 0000000000 | 16-Nov-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 0000 0000000000 00 |
| Quanta Therapeutics | 26-Oct-2021 | Later Stage VC | 0000 | Biotechnology | Pre-Clinical Trials | |
| Lexeo Therapeutics | 09-Sep-2021 | Later Stage VC | 00000 | Biotechnology | Generating Revenue | 000000 00000000 |
Longitude Capital Exits (84)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Velicept Therapeutics | 01-Jul-2022 | Out of Business | |
| 00000 | 30-Jun-2022 | 000000 0000000000 | 000.00 |
| 000000 00000000 | 30-Jun-2022 | 000000000000000000 | 00.00 |
| 000000000 00000000 | 31-May-2022 | 000000000000000000 | 00000 |
| 0000 000000000000 | 11-Feb-2022 | 000000 0000000000 | 000.00 |
| 000000 00000000000 | 08-Feb-2022 | 000000000000000000 | 00.000 |
| 00000 | 31-Dec-2021 | 000 00 00000000 | |
| 00000000 0000 0000 | 17-Dec-2021 | 000000000000000000 | 00.000 |
| Theseus | 07-Oct-2021 | IPO | 00000 |
| Encore Dermatology | 20-Sep-2021 | Out of Business |
Longitude Capital Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Longitude Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Longitude Capital Team (44)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Carolyn Helms | Chief Financial Officer | Menlo Park, CA | |||
| David Hirsch Ph.D | Co-Founder & Managing Director | 00 | 0 | 0 | Boston, MA |
| Juliet Bakker | Co-Founder & Managing Director | 00 | 0 | 0 | Greenwich, CT |
| Marc Galletti | Co-Founder & Managing Director | 0 | 0 | 0 | Menlo Park, CA |
| Gregory Grunberg MD | Managing Director | 00 | 0 | 0 | Menlo Park, CA |
Longitude Capital Co-Investors (167)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| RA Capital Management | 6 | 0 |
|
|
|
| Sofinnova Investments | 0 | 0 | 0 |
|
|
| New Enterprise Associates | 0 | 0 | 0 |
|
|
| Omega Funds | 0 | 0 | 0 |
|
|
| T. Rowe Price | 0 | 0 | 0 |
|
|